Hemispherx BioPharma, Inc (NYSEMKT:HEB) has announced that it has compared its results from the Ampligen data, with the National Institute of Neurological Disorders and Stroke. The research being conducted by the National Institute of Health focuses on Chronic Fatigue Syndrome. Hemispherx believes that the research would be a game changer for patients of the disease. The NIH had updated, the patients, on its research developments, under Francis S. Collins, on March 8 in an open call.

Thomas K. Equels, the CEO of HEB, stated that the company management had met with the delegates of the NIH, to review Apmligen studies, in order to answer questions, vital to gain FDA approval of the drug. The director of NINDS, Walter Koroshetz, had identified the syndrome as a “difficult problem” and had announced plans to include universities and companies to find a solution. It is expected that an estimated 20 NIH institutes would be working on the problem, to identify biomarkers, symptoms, mechanisms and causes of the disease.

Ampligen is widely regarded as the only experimental treatment, for the disease, to have completed phase-2 and 3 clinical trials. It is estimated that a total of 800 patients have been treated with Ampligen. The treatments were conducted under an FDA authorize open-label treatment protocol. However, only patients with severe cases were allowed to take part in the safety study.

Recently, Hemispherx underwent some changes, in its executive management. As per the board’s decisions, William Carter has been terminated from his position, while William M. Mitchell would be the new chairman of the board. The latter had been an independent director, since 1998. The company is yet to update on the new changes, made in light of the ex-chairman’s departure. The board has stated that the move would provide HEB with a competent leadership, which would allow it to achieve its commercial goals and further improve the shareholder value.

Hemispherx BioPharma, Inc (NYSEMKT:HEB) reached a close at $0.163, after gaining 3.23% during the March 10 trading session.